Conference Coverage

Little change in rheumatology faculty coverage in pediatric residency programs in nearly 20 years

Publish date: April 4, 2023

 

AT PRSYM 2023

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA approves Idacio as eighth adalimumab biosimilar in U.S.
MDedge Rheumatology
FDA will review pediatric indication for roflumilast cream
MDedge Rheumatology
New study offers details on post-COVID pediatric illness
MDedge Rheumatology
Abnormal bleeding common among youth with joint hypermobility
MDedge Rheumatology
75 years: A look back on the fascinating history of methotrexate and folate antagonists
MDedge Rheumatology
COVID emergency orders ending: What’s next?
MDedge Rheumatology
A doctor intervenes in a fiery car crash
MDedge Rheumatology
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
MDedge Rheumatology
FDA approves new formulation of Hyrimoz adalimumab biosimilar
MDedge Rheumatology
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
MDedge Rheumatology